Spero posts Q1 net loss of $7.2M; tebipenem HBr PDUFA date June 18, 2026

Spero Therapeutics, Inc.

2026-Q1 EPS reported -$0.13 vs consensus -$0.18 ▲ beat (+29.2%)

Net loss of $7.2M ($0.13 diluted EPS) vs $13.9M loss ($0.25 EPS) in Q1 2025.
Total revenue of $0.3M, down from $5.9M in prior-year quarter.
Cash and equivalents of $56.1M as of March 31, 2026; cash runway into 2028.
GSK-led NDA for tebipenem HBr in cUTI under FDA review with PDUFA date June 18, 2026.
R&D expenses fell to $2.9M from $13.6M due to Phase 3 trial completion.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Spero Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue Total revenue for the first quarter of 2026 was $0.3 million, net income Spero reported a net loss of $7.2 million for the first quarter of 2026, EPS diluted net loss per share of common stock of $0.13.

Period: first quarter ended March 31, 2026
Revenue: Total revenue for the first quarter of 2026 was $0.3 million
Net income: Spero reported a net loss of $7.2 million for the first quarter of 2026
EPS: diluted net loss per share of common stock of $0.13
Result: reported results

Exact text from the filing

Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.

View on SEC.gov

Browse all earnings releases →

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-221567

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.